Cargando…

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern

While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. More...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Ryan P., Maron, Jenny S., Boucau, Julie, Roy, Vicky, Webb, Nicholas E., Bertera, Harry L., Barczak, Amy K., Positives Study Staff, The, Franko, Nicholas, Logue, Jennifer K., Kemp, Megan, Li, Jonathan Z., Zhou, Ling, Hsieh, Ching-Lin, McLellan, Jason S., Siedner, Mark J., Seaman, Michael S., Lemieux, Jacob E., Chu, Helen Y., Alter, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470538/
https://www.ncbi.nlm.nih.gov/pubmed/37535402
http://dx.doi.org/10.1128/mbio.00902-23
_version_ 1785099700397932544
author McNamara, Ryan P.
Maron, Jenny S.
Boucau, Julie
Roy, Vicky
Webb, Nicholas E.
Bertera, Harry L.
Barczak, Amy K.
Positives Study Staff, The
Franko, Nicholas
Logue, Jennifer K.
Kemp, Megan
Li, Jonathan Z.
Zhou, Ling
Hsieh, Ching-Lin
McLellan, Jason S.
Siedner, Mark J.
Seaman, Michael S.
Lemieux, Jacob E.
Chu, Helen Y.
Alter, Galit
author_facet McNamara, Ryan P.
Maron, Jenny S.
Boucau, Julie
Roy, Vicky
Webb, Nicholas E.
Bertera, Harry L.
Barczak, Amy K.
Positives Study Staff, The
Franko, Nicholas
Logue, Jennifer K.
Kemp, Megan
Li, Jonathan Z.
Zhou, Ling
Hsieh, Ching-Lin
McLellan, Jason S.
Siedner, Mark J.
Seaman, Michael S.
Lemieux, Jacob E.
Chu, Helen Y.
Alter, Galit
author_sort McNamara, Ryan P.
collection PubMed
description While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2–3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE: The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.
format Online
Article
Text
id pubmed-10470538
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-104705382023-09-01 Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern McNamara, Ryan P. Maron, Jenny S. Boucau, Julie Roy, Vicky Webb, Nicholas E. Bertera, Harry L. Barczak, Amy K. Positives Study Staff, The Franko, Nicholas Logue, Jennifer K. Kemp, Megan Li, Jonathan Z. Zhou, Ling Hsieh, Ching-Lin McLellan, Jason S. Siedner, Mark J. Seaman, Michael S. Lemieux, Jacob E. Chu, Helen Y. Alter, Galit mBio Research Article While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2–3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE: The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies. American Society for Microbiology 2023-08-03 /pmc/articles/PMC10470538/ /pubmed/37535402 http://dx.doi.org/10.1128/mbio.00902-23 Text en Copyright © 2023 McNamara et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
McNamara, Ryan P.
Maron, Jenny S.
Boucau, Julie
Roy, Vicky
Webb, Nicholas E.
Bertera, Harry L.
Barczak, Amy K.
Positives Study Staff, The
Franko, Nicholas
Logue, Jennifer K.
Kemp, Megan
Li, Jonathan Z.
Zhou, Ling
Hsieh, Ching-Lin
McLellan, Jason S.
Siedner, Mark J.
Seaman, Michael S.
Lemieux, Jacob E.
Chu, Helen Y.
Alter, Galit
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title_full Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title_fullStr Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title_full_unstemmed Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title_short Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
title_sort anamnestic humoral correlates of immunity across sars-cov-2 variants of concern
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470538/
https://www.ncbi.nlm.nih.gov/pubmed/37535402
http://dx.doi.org/10.1128/mbio.00902-23
work_keys_str_mv AT mcnamararyanp anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT maronjennys anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT boucaujulie anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT royvicky anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT webbnicholase anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT berteraharryl anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT barczakamyk anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT positivesstudystaffthe anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT frankonicholas anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT loguejenniferk anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT kempmegan anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT lijonathanz anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT zhouling anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT hsiehchinglin anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT mclellanjasons anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT siednermarkj anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT seamanmichaels anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT lemieuxjacobe anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT chuheleny anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern
AT altergalit anamnestichumoralcorrelatesofimmunityacrosssarscov2variantsofconcern